Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Zeynalov, Emil ^a,c   Jones, Susan M ^a,c   Elliott, J Paul ^b  

^a SWEDISH MEDICAL CENTER   (United States)

^b Department of Neurosurgery   (United States)

^c Swedish Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; BRAIN EDEMA; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; HEMISPHERE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; REPERFUSION; THERAPY DELAY; TIME TO TREATMENT; TRANSLATIONAL RESEARCH; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CEREBRAL ARTERY DISEASE; COMPLICATION; DRUG EFFECTS; PATHOLOGY;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; BLOOD-BRAIN BARRIER; BRAIN EDEMA; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL;

EID: 85028681633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183985     Document Type: Article

References (18)

1. Heiss WD. Malignant MCA Infarction: Pathophysiology and Imaging for Early Diagnosis and Management Decisions. Cerebrovasc Dis. 2016; 41(1–2):1–7. https://doi.org/10.1159/000441627 PMID: 26581023.
2. Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. Int J Mol Sci. 2015; 16(5):9949–75. https://doi.org/10.3390/ijms16059949 PMID: 25941935;
3. Figueroa SA, Zhao W, Aiyagari V. Emergency and critical care management of acute ischaemic stroke. CNS Drugs. 2015; 29(1):17–28. https://doi.org/10.1007/s40263-014-0210-2 PMID: 25391708.
4. Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2005; 25(8):1012–9. https://doi.org/10.1038/sj.jcbfm.9600097 PMID: 15744246.
5. Chelko SP, Schmiedt CW, Lewis TH, Lewis SJ, Robertson TP. Vasopressin-induced constriction of the isolated rat occipital artery is segment dependent. J Vasc Res. 2013; 50(6):478–85. https://doi.org/10.1159/000355265 PMID: 24192548;
6. Wun T, Paglieroni T, Lachant NA. Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Br J Haematol. 1996; 92(4):968–72. PMID: 8616095.
7. Vantyghem MC, Balavoine AS, Wemeau JL, Douillard C. Hyponatremia and antidiuresis syndrome. Ann Endocrinol (Paris). 2011; 72(6):500–12. https://doi.org/10.1016/j.ando.2011.10.001 PMID: 22119069.
8. Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice. PLoS One. 2015; 10(8):e0136121. https://doi.org/10.1371/journal.pone.0136121 PMID: 26275173;
9. Hedna VS, Bidari S, Gubernick D, Ansari S, Satriotomo I, Khan AA, et al. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature. BMC Neurol. 2014; 14:213. https://doi.org/10.1186/s12883-014-0213-0 PMID: 25403760;
10. Zeynalov E, Jones SM, Elliott JP. Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J Vis Exp. 2016; (115). https://doi.org/10.3791/54170 PMID: 27684044.
11. Szmydynger-Chodobska J, Fox LM, Lynch KM, Zink BJ, Chodobski A. Vasopressin amplifies the production of proinflammatory mediators in traumatic brain injury. J Neurotrauma. 2010; 27(8):1449–61. https://doi.org/10.1089/neu.2010.1331 PMID: 20504162;
12. Conivaptan: YM 087. Drugs in R&D. 2004; 5(2):94–7. PMID: 15293869.
13. Villabona C. [Vasopressin receptor antagonists: the vaptans]. Endocrinol Nutr. 2010; 57 Suppl 2:41–52. PMID: 21130961.
14. Lv S, Song HL, Zhou Y, Li LX, Cui W, Wang W, et al. Tumour necrosis factor-alpha affects blood-brain barrier permeability and tight junction-associated occludin in acute liver failure. Liver Int. 2010; 30 (8):1198–210. https://doi.org/10.1111/j.1478-3231.2010.02211.x PMID: 20492508.
15. O’Donnell ME, Duong V, Suvatne J, Foroutan S, Johnson DM. Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent. American journal of physiology Cell physiology. 2005; 289(2):C283–92. https://doi.org/10.1152/ajpcell.00001.2005 PMID: 15800057.
16. Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, et al. The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Critical care medicine. 2008; 36(9):2634–40. https://doi.org/10.1097/CCM.0b013e3181847853 PMID: 18679106;
17. Zeynalov E, Dore S. Low doses of carbon monoxide protect against experimental focal brain ischemia. Neurotoxicity research. 2009; 15(2):133–7. https://doi.org/10.1007/s12640-009-9014-4 PMID: 19384576;
18. Zeynalov E, Nemoto M, Hurn PD, Koehler RC, Bhardwaj A. Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2006; 26(3):414–20. https://doi.org/10.1038/sj.jcbfm.9600196 PMID: 16049424.